Pacira Pharmaceuticals, Inc. Pain Drug Fails Late-Stage Trial
8/2/2013 7:36:33 AM
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
Pacira Pharmaceuticals, Inc. (PCRX: Quote) Thursday said results from a late-stage study with Exparel in intercostal nerve block did not meet the primary endpoint of pain reduction. The stock plunged 12 percent in the extended trade. The company's second pivotal, Phase 3 clinical trial assessed the safety and efficacy of Exparel (bupivacaine liposome injectable suspension) in intercostal nerve block for a surgical procedure known as posterolateral thoracotomy.
Help employers find you! Check out all the jobs and post your resume.